Epidemiology of Alzheimer's disease in Sergipe from 2008 to 2018: hospital morbity and mortality
Keywords:Alzheimer's disease; Epidemiology; Hospital morbidity; Mortality; Sergipe.
Alzheimer's disease is the most common neurodegenerative disease and the main cause of dementia worldwide, being one of the major health challenges in the 21st century. In recent years, dementia has represented the fifth leading cause of death in the world, with about 2.4 million deaths. This study aimed to analyze the epidemiological data on hospital morbidity and mortality caused by Alzheimer's Disease in the State of Sergipe, between the years 2008 and 2018. This is a descriptive, retrospective and cross-sectional epidemiological study conducted with data from DATASUS . In the analyzed period, only 21 hospitalizations were registered, thirteen of which were female, twelve visits were made to patients aged 80 years or older. Data such as race / color were ignored in 18 patients seen. Regarding mortality, 979 deaths were recorded. Most of the residents, 547, were residents of Aracaju. The female sex was the most affected with 645 cases and the most affected age group was that of patients aged 80 years or older, with 697 cases. Through the study it was possible to assess the lack of food in the system, mainly in the Hospital Information System, since there are few cases to be analyzed and some information is not properly registered. It is also necessary to emphasize the importance and contribution of databases such as DATASUS, since the availability of public information is essential for the implementation of health action measures, carried out according to the epidemiological characteristics of the studied diseases.
Agnihotri, A., & Aruoma, O. I. (2020). Alzheimer’s Disease and Parkinson’s Disease: A Nutritional Toxicology Perspective of the Impact of Oxidative Stress, Mitochondrial Dysfunction, Nutrigenomics and Environmental Chemicals. Journal of the American College of Nutrition, 39(1), 16-27.
Alzheimer’s Disease International. (2019). World Alzheimer Report 2019: Attitudes to dementia. Alzheimer’s Disease International (ADI).
Andrews, S. J., Fulton-Howard, B., & Goate, A. (2020). Interpretation of risk loci from genome-wide association studies of Alzheimer’s disease. Lancet Neurology, 19(4), 326-335.
Barrett, B., Schultz, S. K., Luther, S. L., & Friedman, Y. (2020). Mortality and Associated Risk Factors in Community-Dwelling Persons With Early Dementia. Alzheimer Disease & Associated Disorders, 34(1), 40-46.
Bellenguez, C., Grenier-Boley, B., & Lambert, J.-C. (2020). Genetics of Alzheimer’s disease: where we are, and where we are going. Current Opinion in Neurobiology, 61, 40-48.
Benwell, C. S., Davila-Pérez, P., Fried, P. J., Jones, R. N., Travison, T. G., Santarnecchi, E., & Shafi, M. M. (2020). EEG spectral power abnormalities and their relationship with cognitive dysfunction in patients with Alzheimer’s disease and Type 2 Diabetes. Neurobiology of Aging, 85, 83-95.
Brasil. IBGE. (2020). Censo Demográfico 2010. Fonte: http://tabnet.datasus.gov.br/cgi/tabcgi.exe?ibge/cnv/popse.def
Brasil. Ministério da Saúde. (11 de Novembro de 2020). Sistema de Informações sobre Mortalidade (SIM). Fonte: http://tabnet.datasus.gov.br/cgi/tabcgi.exe?sim/cnv/obt10se.def
Brasil. Ministério da Saúde. (11 de Novembro de 2020). Sistema de Informações Hospitalares do SUS (SIH/SUS). Fonte: http://tabnet.datasus.gov.br/cgi/tabcgi.exe?sih/cnv/nrSE.def
Briels, C., Stam, C., Scheltens, P., Bruins, S., Lues, I., & Gouw, A. (2020). In pursuit of a sensitive EEG functional connectivity outcome measure for clinical trials in Alzheimer’s disease. Clinical Neurophysiology, 131(1), 88-95.
CAI, Q., & Jeong, Y. Y. (2020). Mitophagy in Alzheimer’s Disease and Other Age-Related Neurodegenerative Diseases. Cells, 9(150), 1-28.
Carneiro, P., Morais, S., & Pereira, M. d. (2020). Biosensors on the road to early diagnostic and surveillance of Alzheimer's disease. Talanta, 211.
Cheng, A., Wang, J., Ghena, N., Zhao, Q., Perone, I., King, T. M., & Mattson, M. P. (2020). SIRT3 Haploinsufficiency Aggravates Loss of GABAergic Interneurons and Neuronal Network Hyperexcitability in an Alzheimer's Disease Model. Journal of Neuroscience, 40(3), 694-709.
Esperón, J. M. (2017). Pesquisa Quantitativa na Ciência da Enfermagem. Escola Anna Nery.
Franzmeier, N., Neitzel, J., Rubinski, A., Smith, R., Strandberg, O., & Ossenkoppele, R. (2020). Functional brain architecture is associated with the rate of tau accumulation in Alzheimer’s disease. Nature Communication, 11(347).
GATE, D., Saligrama, N., Leventhal, O., YANG, A. C., Unger, M. S., & Middeldorp, J. (2020). Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer’s disease. Nature, 577, 399-404.
GBD 2016 Dementia Collaborators. (2019). Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, 18(1), 88-106.
Gil, A. C. (2002). Como Elaborar Projetos de Pesquisa (4a ed.). Atlas.
Hao, X., Bao, Y., Guo, Y., Yu, M., Zhang, D., Risacher, S. L., & Shen., L. (2020). Multi-modal neuroimaging feature selection with consistent metric constraint for diagnosis of Alzheimer's disease. Medical Image Analysis, 60.
Heneka, M. T. (2020). T cells make a home in the degenerating brain. Nature, 577, 322-323.
Hochman, B., Nahas, F. X., Filho, R. S., & Ferreira, L. M. (2005). Desenhos de pesquisa. Acta Cirúrgica Brasileira.
Janelidze, S., Mattsson, N., Palmqvist, S., & Smith, R. (2020). Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia. Nature Medicine, 26, 379-386.
Jia, L., Quan, M., Fu, Y., Zhao, T., Li, Y., Wei, C., & Wang, Y.-J. (2020). Dementia in China: epidemiology, clinical management, and research advances. Lancet Neurology, 19(1), 81-92.
Karikari, T. K., Pascoal, T. A., Ashton, N. J., Janelidze, S., Benedet, A. L., Rodriguez, J. L., & Savard, M. (2020). Blood Phosphorylated Tau 181 as a Biomarker for Alzheimer's Disease: A Diagnostic Performance and Prediction Modelling Study Using Data From Four Prospective Cohorts. Lancet Neurology, 19(5), 422-433.
Lima-Costa, M. F., & Barreto, S. M. (2003). Tipos de estudos epidemiológicos: conceitos básicos e aplicações na área do envelhecimento. Epidemiologia e Serviços de Saúde.
Loureiro, J. C., Pais, M. V., Stella, F., Radanovic, M., & Teixeira, A. L. (2020). Passive antiamyloid immunotherapy for Alzheimer’s disease. Current Opinion in Psychiatry, 33(3), 284-291.
Möllers, T., Perna, L., Stocker, H., Ihle, P., Schubert, I., & B. S. (2020). Alzheimer's disease medication and outcomes of hospitalisation among patients with dementia. Epidemiology and Psychiatric Sciences, 29(73), 1-9.
Pais, M., Martinez, L., Ribeiro, O., Loureiro, J., Fernandez, R., & Valiengo, L. (2020). Early diagnosis and treatment of Alzheimer’s disease:. Revista Brasileira de Psiquiatria.
Pini, L., Geroldi, C., Galluzzi, S., Baruzzi, R., Bertocchi, M., & Chitò, E. (2020). Age at onset reveals different functional connectivity abnormalities in prodromal Alzheimer’s disease. Brain Imaging and Behavior.
Piovezan, R. D., Oliveira, D., Arias, N., Acosta, D., & Prince, M. J. (2020). Mortality Rates and Mortality Risk Factors in Older Adults with Dementia from Low- and Middle-Income Countries: The 10/66 Dementia Research Group Population-Based Cohort Study. Journal of Alzheimer's Disease, 75, 581-593.
Rubenstein, E., Hartley, S., & Bishop, L. (2020). Epidemiology of Dementia and Alzheimer Disease in Individuals With Down Syndrome. JAMA Neurology, 77(2), 262-264.
Santos, C. d., Bessa, T. A., & Xavier, A. J. (2020). Fatores associados à demência em idosos. Ciência e Saúde Coletiva, 25(2).
Savulich, G., O’Brien, J. T., & Sahakian, B. J. (2020). Are neuropsychiatric symptoms modifiable risk factors for cognitive decline in Alzheimer’s disease and vascular dementia? The British Journal of Psychiatry, 216(1), 1-3.
Scheltens, P., Blennow, K., Breteler, M. M., Strooper, B. d., Frisoni, G. B., Salloway, S., & Flier, W. M. (2016). Alzheimer’s disease. Lancet, 388, 505-517.
Souza, R. K., Barboza, A. F., Gasperin, G., Garcia, H. D., Barcellos, P. M., & Nisihara, R. (2020). Prevalência de demência em pacientes atendidos em um hospital privado no sul do Brasil. Einstein, 18, 1-7.
Suryadevara, V., Klüppel, M., Monte, F. d., & Willis, M. S. (2020). The Unraveling: Cardiac and Musculoskeletal Defects and Their Role in Common Alzheimer Disease Morbidity and Mortality. The American Journal of Pathology, 190(8), 1609-1621.
Webers, A., Heneka, M. T., & Gleeson, P. A. (2019). The role of innate immune responses and neuroinflammation in amyloid accumulation and progression of Alzheimer’s disease. Immunology & Cell Biology, 98(1), 28-41.
Wen, J., Thibeau-Sutre, E., Routier, A., & Diaz-Melo, M. (2020). Convolutional neural networks for classification of Alzheimer's disease: Overview and reproducible evaluation. Medical Image Analysis, 63, 48.
Williams, D. M., Finan, C., Schmidt, A. F., Burgess, S., & Hingorani, A. D. (2020). Lipid Lowering and Alzheimer Disease Risk: A Mendelian Randomization Study. Annals of Neurology, 87(1), 30-39.
Zendehbad, A. S., Noroozianb, M., Shakibac, A., Kargard, A., & Davoudkhanie, M. (2020). Validation of Iranian Smell Identification Test for screening of mild cognitive impairment and Alzheimer’s disease. Applied Neuropsychology: Adult, 1-6.
Zhou, Y., Song, W. M., Andhey, P. S., Swain, A., Levy, T., Miller, K. R., & Grover, S. (2020). Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer’s disease. Nature Medicine, 26, 131-142.
How to Cite
Copyright (c) 2021 João Paulo Siqueira Correia; André Luiz Baião Campos; Samara Siqueira Correia; Crysvânia Santos Nascimento
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.